X
<

Where Is Novartis Positioned after 3Q17?

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 2
Where Is Novartis Positioned after 3Q17? PART 2 OF 12

How Novartis’s Cosentyx Is Positioned after 3Q17

Cosentyx revenue trends

In 3Q17, Novartis’s (NVS) Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ (quarter-over-quarter).

How Novartis’s Cosentyx Is Positioned after 3Q17

Interested in NVS? Don't miss the next report.

Receive e-mail alerts for new research on NVS

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Future 5 trial

In November 2017, Novartis presented the results from its Future 5 trial, wherein Cosentyx demonstrated a reduction in signs and symptoms of psoriatic arthritis (or PsA) and substantial inhibition in the progression of joint structural damage in individuals with PsA compared with placebo therapy.

In the Future 5 trial, 996 participants were randomized to receive Cosentyx 300 mg (milligrams) with a loading dose (or LD), Cosentyx 150 mg with LD, and Cosentyx 150 mg without LD. Patients receiving Cosentyx demonstrated substantial progress in the signs and symptoms of PsA, according to the American College of Rheumatology (or ACR), with response criteria of 20% improvement (ACR20) at 16 weeks.

By comparison, Eli Lilly’s (LLY) Taltz, Amgen’s (AMGN) Enbrel, and Johnson & Johnson’s (JNJ) Stelara reported revenues of ~$151.3 million, ~$1.4 billion, and ~$1.1 billion, respectively, in 3Q17. Notably, the Vanguard FTSE All-World ex-US ETF (VEU) invests ~0.67% of its total portfolio holdings in Novartis.

X

Please select a profession that best describes you: